DENALI THERAPEUTICS INC (DNLI)

US24823R1059 - Common Stock

20.77  +0.89 (+4.48%)

Premarket: 20.77 0 (0%)

Full profile views are only available for registered users, you can see which data is available below.

Examples of complete profiles are available for MSFT and AAPL.

Registered users have access to more data. Please register or login for additional data.

DENALI THERAPEUTICS INC

NASDAQ:DNLI (3/27/2024, 8:08:50 PM)

Premarket: 20.77 0 (0%)

20.77

+0.89 (+4.48%)

Chartmill TA Rating
Chartmill Setup Rating
Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
Chartmill FA Rating
Valuation
Growth
Profitability
Health
Dividend
Overview
Earnings (Last)
Earnings (Next)
Ins Owners
Inst Owners
Market Cap2.96B
Shares
PEN/A
Fwd PEN/A
Dividend YieldN/A
Analysts
IPO
Stock Screener Links
Screen Image

Nasdaq Stock Screener

Find more stocks on Nasdaq

Screen Image

USA Stock Screener

Find more stocks on the USA

Screen Image

GICS Sector Stock Screener

Find competitors from the same sector on the USA

Screen Image

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Screen Image

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Screen Image

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Screen Image

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

DNLI Daily chart

Company Profile

Denali Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of a portfolio of product candidates for neurodegenerative diseases. The company is headquartered in South San Francisco, California and currently employs 447 full-time employees. The company went IPO on 2017-12-08. The firm is focused on developing a portfolio of product candidates engineered to cross the blood-brain barrier (BBB) for neurodegenerative diseases and lysosomal storage disease. The Company’s clinical-stage programs include Antibody Transport Vehicle (ATV): triggering receptors expressed on myeloid cells 2 (TREM2), Protein Transport Vehicle (PTV): progranulin (PGRN), eukaryotic initiation factor 2 B (eIF2B), receptor-interacting serine/threonine protein kinase 1 (RIPK1), Enzyme Transport Vehicle (ETV): iduronate 2-sulfatase (IDS) and leucine-rich repeat kinase 2 (LRRK2), which are in various Phases ranging from Phase I through Phase III. The Company’s product candidates include DNL310, TAK-594/DNL593, TAK-920/DNL919, BIIB122/DNL151, DNL343, SAR443820/DNL788 and SAR443122/DNL758. The firm engineers its product candidates to cross the BBB, and act directly in the brain.

Company Info

DENALI THERAPEUTICS INC

161 Oyster Point Blvd

South San Francisco CALIFORNIA 94080

P: 16508668548

CEO: Ryan J. Watts

Employees: 447

Website: https://www.denalitherapeutics.com

DNLI News

News Image6 days ago - ChartmillWhich stocks are moving after the closing bell on Friday?

After hours stock analysis on 2024-03-22: top gainers and losers in today's session.

News Image9 days ago - Flagship PioneeringFlagship Pioneering Named to Fast Company's Annual List of the World's Most Innovative Companies of 2024

/PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, has been named to Fast Company's prestigious list of the World's Most Innovative...

News Image14 days ago - InvestorPlaceTo the Moon and Beyond: 7 Stocks With Cosmic Potential

With the Fear and Greed Index at 69, it's an opportune to wager on these attractive Stocks with Moonshot Potential.

News Imagea month ago - Seeking AlphaDenali spikes after $500M private placement (NASDAQ:DNLI)

Denali Therapeutics (DNLI) stock rises amid plans to raise $500M through a private placement. Read more here.

News Imagea month ago - Denali Therapeutics Inc.Denali Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights
News Imagea month ago - Denali Therapeutics Inc.Denali Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights

SOUTH SAN FRANCISCO, Calif., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNLI), a biopharmaceutical company developing a broad...

DNLI Twits

Here you can normally see the latest stock twits on DNLI, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.

Example Twits:

Twits example